Corbus Pharmaceuticals Holdings, Inc. is an emerging drug development company focused on the development and commercialization of Resunab™, the company’s lead product candidate to treat rare and severe life-threatening fibrotic and inflammatory diseases such as scleroderma and cystic fibrosis. The company recently announced that Yuval Cohen, Ph.D., Corbus’ CEO, will be presenting at VirtualInvestorConferences.com. This is a live, interactive, online event that will take place on Thursday, December 4, at 11:30 a.m. (Eastern Standard Time).
Systemic sclerosis (SSc), more commonly called scleroderma, is a rheumatic autoimmune disease. It affects not only the skin but other organs as well, due to an immune system dysfunction. The disease is associated with skin tightening and thickening, inflammation, and scarring of the organs, which can provoke serious health issues in the lungs, kidneys, heart, and intestine. SSc is very rare condition, as only 75,000 to 100,000 people have SSc in the United States.
Corbus Pharmaceuticals is focused on developing innovative therapies for rare diseases with clear, urgent unmet needs like scleroderma. Representing the company, Dr. Cohen will provide a valuable update on Corbus’ progress and anticipated clinical developments regarding Resunab™. Resunab is a new synthetic oral drug and specialized pro-resolving mediator that acts as anti-inflammatory and anti-fibrotic. These characteristics make Resunab potentially ideal for the treatment of diffuse scleroderma and cystic fibrosis.
The VirtualInvestorConferences have been held once a month since 2010, thanks to BetterInvesting (NAIC) and PRNewswire. The events are “designed to replicate the look and feel of location-based investor conferences,” as noted in a press release. This approach allows companies to meet directly with retail investors. The presentation will be in real-time, where participants can ask questions in the presentation hall and in the “virtual trade book.” It can be accessed on the website (VirtualInvestorConferences.com) and will be accessible on-demand for 90 days.